Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy

Published on Oct 23, 2016in Journal of Clinical Oncology32.956
· DOI :10.1200/JCO.2016.67.9647
Rahul D. Tendulkar21
Estimated H-index: 21
(Cleveland Clinic),
Shree Agrawal7
Estimated H-index: 7
(Case Western Reserve University)
+ 17 AuthorsAndrew J. Stephenson57
Estimated H-index: 57
(Case Western Reserve University)
Sources
Abstract
PurposeWe aimed to update a previously published, multi-institutional nomogram of outcomes for salvage radiotherapy (SRT) following radical prostatectomy (RP) for prostate cancer, including patients treated in the contemporary era.MethodsIndividual data from node-negative patients with a detectable post-RP prostate-specific antigen (PSA) treated with SRT with or without concurrent androgen-deprivation therapy (ADT) were obtained from 10 academic institutions. Freedom from biochemical failure (FFBF) and distant metastases (DM) rates were estimated, and predictive nomograms were generated.ResultsOverall, 2,460 patients with a median follow-up of 5 years were included; 599 patients (24%) had a Gleason score (GS) ≤ 6, 1,387 (56%) had a GS of 7, 244 (10%) had a GS of 8, and 230 (9%) had a GS of 9 to 10. There were 1,370 patients (56%) with extraprostatic extension (EPE), 452 (18%) with seminal vesicle invasion (SVI), 1,434 (58%) with positive surgical margins, and 390 (16%) who received ADT (median, 6 months)....
📖 Papers frequently viewed together
721 Citations
315 Citations
230 Citations
References21
Newest
#1Christian CarrieH-Index: 49
#2Ali HasbiniH-Index: 10
Last. Sophie DussartH-Index: 9
view all 22 authors...
Summary Background How best to treat rising prostate-specific antigen (PSA) concentration after radical prostatectomy is an urgent clinical question. Salvage radiotherapy delays the need for more aggressive treatment such as long-term androgen suppression, but fewer than half of patients benefit from it. We aimed to establish the effect of adding short-term androgen suppression at the time of salvage radiotherapy on biochemical outcome and overall survival in men with rising PSA following radica...
230 CitationsSource
#1Nicola Fossati (UniSR: Vita-Salute San Raffaele University)H-Index: 36
#2R. Jeffrey Karnes (Mayo Clinic)H-Index: 70
Last. Alberto Briganti (UniSR: Vita-Salute San Raffaele University)H-Index: 96
view all 17 authors...
Abstract Background Early salvage radiation therapy (eSRT) represents a treatment option for patients who experience a prostate-specific antigen (PSA) rise after radical prostatectomy (RP); however, the optimal PSA level for eSRT administration is still unclear. Objective To test the impact of PSA level on cancer control after eSRT according to pathologic tumour characteristics. Design, setting, and participants The study included 716 node-negative patients with undetectable postoperative PSA wh...
71 CitationsSource
#1Jonathan I. Epstein (Johns Hopkins University)H-Index: 163
#2Lars Egevad (KI: Karolinska Institutet)H-Index: 79
Last. Peter A. Humphrey (Yale University)H-Index: 88
view all 6 authors...
In November, 2014, 65 prostate cancer pathology experts, along with 17 clinicians including urologists, radiation oncologists, and medical oncologists from 19 different countries gathered in a consensus conference to update the grading of prostate cancer, last revised in 2005. The major conclusions
1,303 CitationsSource
#1Robert B. Den (UM: University of Michigan)H-Index: 42
#2Kasra Yousefi (UM: University of Michigan)H-Index: 21
Last. R. Jeffrey Karnes (UM: University of Michigan)H-Index: 2
view all 11 authors...
Purpose The optimal timing of postoperative radiotherapy (RT) after radical prostatectomy (RP) is unclear. We hypothesized that a genomic classifier (GC) would provide prognostic and predictive insight into the development of clinical metastases in men receiving post-RP RT and inform decision making. Patients and Methods GC scores were calculated from 188 patients with pT3 or margin-positive prostate cancer, who received post-RP RT at Thomas Jefferson University and Mayo Clinic between 1990 and ...
149 CitationsSource
#1Matthew R. Cooperberg (UCSF: University of California, San Francisco)H-Index: 74
#2Elai DavicioniH-Index: 52
Last. R. Jeffrey Karnes (Mayo Clinic)H-Index: 70
view all 6 authors...
Background: Risk prediction models that incorporate biomarkers and clinicopathologic variables may be used to improve decision making after radical prostatectomy (RP). We compared two previously validated post-RP classifiers—the Cancer of the Prostate Risk Assessment Postsurgical (CAPRA-S) and the Decipher genomic classifier (GC)—to predict prostate cancer–specific mortality (CSM) in a contemporary cohort of RP patients. Objective: To evaluate the combined prognostic ability of CAPRA-S and GC to...
138 CitationsSource
#1Thomas WiegelH-Index: 50
#2Detlef BartkowiakH-Index: 14
Last. Kurt Miller (Charité)H-Index: 73
view all 21 authors...
Background: Local failure after radical prostatectomy (RP) is common in patients with cancer extending beyond the capsule. Three prospectively randomized trials demonstrated an advantage for adjuvant radiotherapy (ART) compared with a wait-and-see (WS) policy. Objective: To determine the efficiency of ART after a 10-yr follow-up in the ARO 96–02
251 CitationsSource
#1Maria Pearse (Auckland City Hospital)H-Index: 9
#2Carol Fraser-Browne (Auckland City Hospital)H-Index: 7
Last. Andrew KneeboneH-Index: 29
view all 20 authors...
Objectives To test the hypothesis that observation with early salvage radiotherapy (SRT) is not inferior to ‘standard’ treatment with adjuvant RT (ART) with respect to biochemical failure in patients with pT3 disease and/or positive surgical margins (SMs) after radical prostatectomy (RP). To compare the following secondary endpoints between the two arms: patient-reported outcomes, adverse events, biochemical failure-free survival, overall survival, disease-specific survival, time to distant fail...
91 CitationsSource
#1Richard K. Valicenti (UC Davis: University of California, Davis)H-Index: 43
#2Ian M. Thompson (University of Texas Health Science Center at San Antonio)H-Index: 110
Last. Martha M. FaradayH-Index: 11
view all 12 authors...
Purpose: The purpose of this guideline was to provide a clinical framework for the use of radiation therapy after radical prostatectomy as adjuvant or salvage therapy. Methods and Materials: A systematic literature review using PubMed, Embase, and Cochrane database was conducted to identify peer-reviewed publications relevant to the use of radiation therapy after prostatectomy. The review yielded 294 articles; these publications were used to create the evidence-based guideline statements. Additi...
135 CitationsSource
#1Michel BollaH-Index: 56
#2Hein Van Poppel (Katholieke Universiteit Leuven)H-Index: 26
Last. Laurence Collette (European Organisation for Research and Treatment of Cancer)H-Index: 86
view all 19 authors...
Summary Background We report the long-term results of a trial of immediate postoperative irradiation versus a wait-and-see policy in patients with prostate cancer extending beyond the prostate, to confirm whether previously reported progression-free survival was sustained. Methods This randomised, phase 3, controlled trial recruited patients aged 75 years or younger with untreated cT0–3 prostate cancer (WHO performance status 0 or 1) from 37 institutions across Europe. Eligible patients were ran...
589 CitationsSource
#1Alberto BrigantiH-Index: 96
#2Thomas WiegelH-Index: 50
Last. Hein Van Poppel (Katholieke Universiteit Leuven)H-Index: 26
view all 14 authors...
Background: Previous randomised trials demonstrated that adjuvant radiation therapy (aRT) improves cancer control in patients with pT3 prostate cancer (PCa). However, there is currently no evidence supporting early salvage radiation therapy (eSRT) as equivalent to aRT in improving freedom from biochemical recurrence (BCR) after radical prostatectomy (RP). Objective: To evaluate BCR-free survival for aRT versus observation followed by eSRT in cases of relapse in patients undergoing RP for pT3pN0,...
141 CitationsSource
Cited By177
Newest
#1Pirus Ghadjar (University of Bern)H-Index: 29
#2Stefanie HayozH-Index: 12
Last. Ludwig Plasswilm (University of Bern)H-Index: 15
view all 72 authors...
Abstract null null Background null Salvage radiotherapy (SRT) is utilized for biochemical progression of prostate cancer after radical prostatectomy (RP). null null null Objective null To report the outcomes of the SAKK 09/10 trial comparing conventional and dose-intensified SRT. null null null Design, setting, and participants null SAKK 09/10 was a randomized, multicenter, phase 3 trial that recruited men with biochemical progression after RP. null null null Intervention null Patients were rand...
2 CitationsSource
#1N. Benziane-Ouaritini (Argonne National Laboratory)
#2P. Sargos (Argonne National Laboratory)H-Index: 7
Last. I. LatorzeffH-Index: 9
view all 5 authors...
Resume null null Objectif de l’etude null La prostatectomie totale est un standard de traitement pour les patients atteints d’un cancer de prostate localise non metastatique. Pres de 30 % des patients operes, verront se developper une rechute biochimique dans les dix annees suivant la prostatectomie totale. De plus, 30 % des cancers traites chirurgicalement presenteront des caracteristiques pathologiques agressives majorant ce risque de rechute biochimique. null null null Materiel et Methodes nu...
Source
#1Nicholas G. Zaorsky (Penn State Cancer Institute)H-Index: 28
#2Jeremie Calais (UCLA: University of California, Los Angeles)H-Index: 20
Last. Amar U. Kishan (UCLA: University of California, Los Angeles)H-Index: 19
view all 7 authors...
More than 40% of men with intermediate-risk or high-risk prostate cancer will experience a biochemical recurrence after radical prostatectomy. Clinical guidelines for the management of these patients largely focus on the use of salvage radiotherapy with or without systemic therapy. However, not all patients with biochemical recurrence will go on to develop metastases or die from their disease. The optimal pre-salvage therapy investigational workup for patients who experience biochemical recurren...
Source
#1Steven N. SeyedinH-Index: 7
#2John M. WatkinsH-Index: 13
Last. John M. BuattiH-Index: 70
view all 11 authors...
Source
#1Fang-Ze Wei (Peking Union Medical College)H-Index: 1
#2Shi-Wen Mei (Peking Union Medical College)H-Index: 1
Last. Qian Liu (Peking Union Medical College)H-Index: 65
view all 9 authors...
Colorectal cancer (CRC) is a common digestive tract tumor worldwide. In recent years, neoadjuvant chemoradiotherapy (CRT) has been the most comprehensive treatment for locally advanced rectal cancer (LARC). In this study, we explored immune infiltration in rectal cancer (RC) and identified immune-related differentially expressed genes (IRDEGs). Then, we identified response markers in datasets in GEO databases by principal component analysis (PCA). We also utilized three GEO datasets to identify ...
Source
#1Ji-Jin Yao (SYSU: Sun Yat-sen University)H-Index: 5
#2Li Lin (SYSU: Sun Yat-sen University)H-Index: 23
Last. Ying Sun (SYSU: Sun Yat-sen University)H-Index: 54
view all 7 authors...
Purpose This study aimed to develop web-based nomograms to precisely predict survival outcomes in patients with non-metastatic nasopharyngeal carcinoma (NPC) in an endemic area. Materials and Methods A total of 10,126 patients who underwent radical intensity-modulated radiotherapy at Sun Yat-sen University Cancer Center (SYSUCC) from 2009 to 2015 were analyzed. We assigned patients into a training cohort (SYSUCC-A, n=6,751) and an internal validation cohort (SYSUCC-B, n=3,375) based on computer-...
Source
#1Sophia C. Kamran (Harvard University)H-Index: 16
Source
#1Akram Al-IbraheemH-Index: 7
#1Akram Al-Ibraheem (UCLA: University of California, Los Angeles)
Last. Ramiz Abu-HijlihH-Index: 4
view all 10 authors...
OBJECTIVES Prostate-specific membrane antigen (PSMA) PET/computed tomography (CT) is a novel imaging tool with an evolving role in the management of prostate cancer. This study aims to retrospectively evaluate the impact of 68Ga-PSMA PET/CT on prostate cancer staging and definitive radiation therapy planning. METHODS Between April 2015 and June 2020, 366 men with prostate cancer were evaluated with 68Ga-PSMA PET/CT. Of these, 108 patients had PSMA PET/CT before radiation therapy. Radiation was g...
Source
#1M.A. Arega (Harvard University)H-Index: 2
#2David Yang (Brigham and Women's Hospital)H-Index: 6
Last. Vinayak Muralidhar (Brigham and Women's Hospital)H-Index: 16
view all 10 authors...
PURPOSE Following radical prostatectomy, men with adverse pathologic features or a persistent post-operative detectable PSA are candidates for postoperative radiation therapy (PORT). Previous data have suggested disparities in receipt of adjuvant radiation therapy for adverse pathologic features according to travel distance. Among patients without adverse pathologic features (pT2 disease and negative margins), the main indication for PORT is a persistent post-operative detectable PSA. However, i...
Source
#1Srinivas Chilukuri (Apollo Hospitals)H-Index: 2
#2Vedang MurthyH-Index: 26
Three contemporary randomised controlled trials (RCTs) namely RAVES, RADICALS, and GETUGAFU 17 were published recently addressing the long-standing debate on "adjuvant (aRT) versus salvage radiation therapy (SRT)" in patients undergoing radical prostatectomy (RP). Although the three recent trials which differ in their design are not mature enough to report endpoints of metastases free survival (MFS) or overall survival, they have unequivocally shown that early SRT was either similar or non-infer...
Source